Autoimmune Disease Clinical Trial in Bethesda MD
Are you healthy and looking to help advance medical science?
You may be eligible to participate in a autoimmune disease clinical study, and could be compensated for your time.
Are you healthy and looking to help advance medical science? You may be eligible to participate in a autoimmune disease clinical study, and could be compensated for your time.
Details for the study
PARTICIPANT INCLUSION CRITERIA: 1. Children age 5 years and above and adults referred to the NIH with chronic or recurring respiratory infections will be eligible for participation. 2. Males and females will be considered without regard to race or ethnicity or upper age limit. 3. Emphasis will be primarily on non CF bronchiectasis for elucidation of mechanisms of infection susceptibility. However, select patients with cystic fibrosis or acquired immune defects (such as HIV) may be studied if relevant host defects are suspected or if needed for comparison purposes or to evaluate and study the management of chronic pathogen associated conditions such as nontuberculous mycobacterial infections or allergic bronchopulmonary aspergillosis. 4. Subjects must have a primary or referring physician 5. Subjects must be willing to have samples stored INCLUSION CRITERIA FOR RELATIVES: As a part of this protocol we may obtain blood, sputum, urine, or buccal swabs from some blood relatives of patients on the study, with the hope of isolating and characterizing the primary host defense defect(s) or genetic links responsible for airway infection susceptibility and/or bronchiectasis seen within families. Male and female relatives will be accepted without limitation due to age. These relatives may have pertinent disease-related history obtained, but will neither receive treatment nor have any other protocol procedures done unless they are enrolled on the study. PARTICIPANT EXCLUSION CRITERIA: 1. We wish to avoid enrolling subjects, especially children, who have common respiratory problems (aeroallergen sensitivity, asthma, gastric esophageal reflux) that are not associated with an underlying abnormality in host defenses. Evidence of significance of chronic or recurring infections suggestive of an underlying airway surface or systemic host defense defect should be documented by one or more of the following: a) sinus or lower airway cultures positive for bacterial, fungal, or mycobacterial pathogens characteristic of these defects; or b) radiographic evidence of sinusitis with mucosal thickening and/or air-fluid levels; or c) radiographic evidence of bronchiectasis; d) severity of otitis media requiring placement of tympanic membrane pressure equalization tubes; e) severity of sinusitis requiring surgical intervention. 2. Patients who are unable or unwilling to provide informed consent either directly or via appropriately designated surrogate. 3. Any patient who, in the opinion of the Investigator, is unable or unwilling to comply with regular follow-up or is unlikely to provide pertinent information regarding disease progression or response to treatment may be excluded from longitudinal follow-up. 4. Children under the age of 5 will be excluded from this protocol. When a pediatric subject reaches age 18, continued participation will require reconsenting with the adult consent document.